Welcome to our dedicated page for Greater Cannabis news (Ticker: GCAN), a resource for investors and traders seeking the latest updates and insights on Greater Cannabis stock.
Greater Cannabis Company, Inc. (OTC: GCAN), also known as GCANRx, generates news primarily as a clinical stage biopharmaceutical company focused on cannabinoid therapeutics for neuropsychiatric disorders. News coverage often centers on its progress in developing a proprietary neuroprotective cannabinoid therapy, particularly for Autism Spectrum Disorder (ASD) and related conditions.
Readers following GCAN news can expect updates on preclinical and clinical milestones. The company has reported initiation and completion of preclinical studies that assessed anti-inflammatory, anti-oxidative and cytoprotective effects of its therapeutic in microglial cell models. It has also announced regulatory interactions and approvals, including submission of a Phase 2 clinical trial application to the Israel Ministry of Health and subsequent final approval for a double blind, placebo controlled Phase II trial in pediatric ASD patients.
GCANRx news also highlights its collaborations and scientific recognition. Releases have described its license and research agreement with Shaare Zedek Scientific, the role of Dr. Adi Aran as inventor and strategic advisor, and the involvement of Professor Tal Burstyn-Cohen’s laboratory through Yissum in preclinical work. The company has been featured in the American Journal of Endocannabinoid Medicine in the context of autism and cannabis research, and its scientific advisor has appeared in media coverage on cannabinoid therapies.
From a capital markets perspective, GCAN-related news includes corporate actions and trading status developments, such as a 1-for-1,500 reverse stock split and uplisting steps within the OTC market structure, including approval for quotation on the OTCQB Venture Market. The company has also issued updates on exploring strategic alternatives, mentioning interest from businesses in artificial intelligence and quantum computing.
This news page aggregates these types of announcements so investors and observers can review GCANRx’s research progress, regulatory events, collaborations and capital markets disclosures in one place.
Greater Cannabis Company (GCAN) has entered a licensing agreement with Shaare Zedek Scientific Ltd. for a novel cannabinoid therapy aimed at treating autism, schizophrenia, and other neuropsychiatric disorders. This partnership includes a joint research development initiative led by Dr. Adi Aran from Shaare Zedek Medical Center, known for its extensive clinical research. Dr. Aran’s previous studies demonstrated significant improvements in behavioral issues for autistic children using cannabis-based therapies.
The Greater Cannabis Company (OTCQB: GCAN) has announced a collaboration with Israel's Phytor LTD to develop cannabinoid and botanical-based therapeutics targeting dermatological and chronic ailments. Led by Dr. Yehoshua Maor, Phytor is recognized for its expertise in plant-based therapeutics. This partnership aims to create more effective, natural solutions that can provide rapid relief compared to conventional treatments. Both companies will integrate their technologies to enhance product offerings for consumer and commercial use.
The Greater Cannabis Company (OTCQB: GCAN) announced the reinstatement of its common stock for trading on the OTCQB Venture Market after a compliance review. This upgrade reflects adherence to high financial standards and improved corporate governance, which the Company believes will enhance investor benefits.
The move is expected to increase transparency, reporting standards, and liquidity, as the OTCQB is viewed as an established public market by the SEC. This tier is known to improve awareness and analyst coverage for companies.
Greater Cannabis Co. (OTC: GCAN) announced that CEO Aitan Zacharin will present at the Benzinga Virtual Cannabis Investor Conference on February 26th at 10:35 AM EST. The presentation will last approximately 20 minutes and will cover an overview of the company's business, technology, and recent progress. GCAN encourages both individual and institutional investors to attend using a free spectator pass available online.
The company specializes in developing innovative cannabinoid delivery systems aimed at enhancing patient experience and efficacy.